Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Trial Evaluating Reprise Biomedical's Miro3D Wound Matrix and Standard of Care Versus Standard of Care Alone in Treating Wagner Grade 1 Diabetic Foot Ulcers and Dehiscence

NCT06939686 is registered in ClinicalTrials.gov with Reprise Biomedical, Inc. as lead sponsor.

NCT NCT06939686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06939686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Trial Evaluating Reprise Biomedical's Miro3D Wound Matrix and Standard of Care Versus Standard of Care Alone in Treating Wagner Grade 1 Diabetic Foot Ulcers and Dehiscence
Lead sponsor
Reprise Biomedical, Inc.
Phase
Not applicable
Overall status
Recruiting
Start date
November 1, 2024
Completion date
July 31, 2026
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chronic wound of the lower limb (leg ulcer or foot ulcer), diabetic foot ulcers (dfus)